These chemotherapeutics depend solely on p53 for intrinsic apoptosis pathway induction and hence the molecular pathway of TRAIL provides a solution circumventing tumour treatment resistance acquired through mutations in p53. This evidence concerns the gene TP53 and neoplasm.